Literature DB >> 1444509

Alopecia areata. A review of therapy, efficacy, safety, and mechanism.

V C Fiedler.   

Abstract

Although it is clear from the foregoing that some of the drugs and chemicals used to treat severe alopecia areata are efficacious to some degree, it is impossible to draw any meaningful comparisons among the data outlined in Tables 1 and 2. Virtually all of the studies were designed differently. Differences in chronicity and extent of disease as well as history of previous treatment resistance may significantly affect efficacy data even as two investigators compare the same drug. Drug-induced hair regrowth in alopecia areata may be very slow; a cosmetic response may take 1 to 2 years to achieve. Efficacy determinations made at shorter intervals may, therefore, not reflect true therapeutic potential. Efficacy end points vary significantly and need to be standardized. From a practical standpoint, scalp hair coverage that is deemed by the patient to be cosmetically acceptable seems to be a reasonable efficacy end point to report. Maintenance of cosmetic effect with continued treatment and/or following discontinuation of treatment also is useful to document. Table 3 outlines my approach to therapy of alopecia areata. Topical treatments often must be used for as long as 3 months before evidence of regrowth can be seen. In my experience with severe disease, if topical treatments cannot control a flare or induce regrowth, then the patient will often require either lengthy or frequent courses of systemic steroids. In my experience, prednisone doses as low as 20 mg/d may be associated with aseptic neurosis of the hip or severe gastrointestinal bleeding. Severe alopecia areata is a disease for which all therapies are, at best, palliative and, at worst, potentially harmful to patients who are usually otherwise very healthy. The psychosocial significance of this disease is enormous. The insights shared by a long-time sufferer of the disease mirror those expressed by the many patients with whom I have worked during the past 12 years. Three key elements to effectively treat the patient are (1) to help the patient understand the disease; (2) to encourage the patient to share his or her feelings with the physician, family, friends, and other sufferers of the disease; and (3) to help the patient to maintain a sense of hope for future scientific knowledge and treatment of the disease. With a thorough knowledge of the potential benefits and risks of each treatment or combination treatment, the physician with the patient's understanding and cooperation may then embark on what may be in severe cases a lengthy and sometimes unproductive therapeutic process.

Entities:  

Mesh:

Year:  1992        PMID: 1444509     DOI: 10.1001/archderm.128.11.1519

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

Review 1.  Treatments for androgenetic alopecia and alopecia areata: current options and future prospects.

Authors:  V M Meidan; E Touitou
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata.

Authors:  Cm Kuldeep; Himanshu Singhal; Ashok Kumar Khare; Asit Mittal; Lalit K Gupta; Anubhav Garg
Journal:  Int J Trichology       Date:  2011-01

3.  Extensive alopecia areata: not necessarily recalcitrant to therapy!

Authors:  Deepal Deshpande; Rachita Dhurat; Punit Saraogi; Sunil Mishra; Chitra Nayak
Journal:  Int J Trichology       Date:  2011-07

4.  Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.

Authors:  Shahin Aghaei
Journal:  BMC Dermatol       Date:  2005-05-26

5.  Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata.

Authors:  In Kwon Yeo; Eun Jung Ko; Yeon A No; Ee Seok Lim; Kui Young Park; Kapsok Li; Beom Joon Kim; Seong Jun Seo; Myeung Nam Kim; Chang Kwun Hong
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

6.  A study to evaluate the efficacy of various topical treatment modalities for alopecia areata.

Authors:  Vidyadhar R Sardesai; Smita Prasad; Trupti D Agarwal
Journal:  Int J Trichology       Date:  2012-10

7.  Simvastatin/Ezetimibe Therapy for Recalcitrant Alopecia Areata: An Open Prospective Study of 14 Patients.

Authors:  Joong-Woon Choi; Dong-Woo Suh; Bark-Lynn Lew; Woo-Young Sim
Journal:  Ann Dermatol       Date:  2017-10-30       Impact factor: 1.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.